Home › NCT07717502

Ripening Approaches for Prompt Induction and Delivery - Sequential Versus Concurrent Dilapan-S and Misoprostol to Achieve Vaginal Delivery (RAPID-DS)

Who can join

Ages 18 and older · Women

Inclusion Criteria:

* Nulliparous patients with singleton pregnancies with vertex lie at term receiving prenatal care that are eligible for outpatient cervical ripening will be eligible

Exclusion Criteria:

* age less than 18,
* suspected major fetal anomalies (including suspected or proven chromosome anomalies, congenital cardiac disease expected to require neonatal intervention, and multiple anomalies suggestive of a complex syndrome),
* fetal growth restriction
* oligohydramnios
* prior full thickness
* uterine scar
* placenta previa,
* low-lying placenta,
* premature rupture of amniotic membranes,
* cervical dilation \> 2 cm
* modified Bishop score \> 4
* residence greater than 60 minutes from the hospital

About the study

The purpose of this study is to compare the effectiveness of sequential versus combined multimodal cervical ripening strategies to achieve vaginal delivery within 24 hours among nulliparous patients with singleton, vertex pregnancies at term undergoing induction of labor.

What is being tested

• Sequential Cervical Ripening (combination product)
• Inpatient Combined Cervical Ripening (combination product)

Sponsor: Ochsner Health System · Participants: 260 · Started: Aug 18, 2026

Contact the study team

• Frank Williams, MD · Phone: 205-994-4820
• Ken Bode · Phone: 504-842-1936

Official record on ClinicalTrials.gov — NCT07717502

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.